Physician profile
Michael Cappelli
NPI 1194702928
$1,182.29
in general payments reported to CMS, 2019-2025
27 companies · $78.33 in 2025
The $78.33 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.26 · 2020: $88.10 · 2021: $171 · 2022: $527 · 2023: $148 · 2024: $151 · 2025: $78.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $190.10 | 2021-2024 | |
| Daiichi Sankyo INC. | $166.44 | 2020-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $88.40 | 2021-2022 | |
| Genzyme Corporation | $66.59 | 2023-2024 | |
| Sobi, INC | $64.76 | 2022 | |
| Eisai INC. | $62.02 | 2021-2023 | |
| Pfizer INC. | $55.68 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $48.27 | 2022-2025 | Monoferric |
| Novocure INC. | $45.16 | 2025 | Optune Gio |
| Incyte Corporation | $35.12 | 2022-2025 | Jakafi |
| Amgen INC. | $34.59 | 2022 | |
| Dendreon Pharmaceuticals LLC | $33.40 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.18 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $32.75 | 2022 | |
| Amag Pharmaceuticals, INC. | $24.55 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.96 | 2022 | |
| Pharmaessentia USA Corporation | $21.57 | 2024 | Besremi |
| Coherus Oncology, INC. | $21.25 | 2022 | |
| Beigene USA, INC. | $17.37 | 2023 | Brukinsa |
| Octapharma USA, INC. | $17.22 | 2022 | |
| Progenics Pharmaceuticals, INC. | $16.84 | 2023 | Pylarify |
| Celgene Corporation | $16.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.50 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.63 | 2022 | |
| Seagen INC. | $13.50 | 2022 | |
| Janssen Biotech, INC. | $13.39 | 2022 | |
| Elekta, INC. | $10.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cappelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.